- Home
- CTNM vs BWAY Comparison
CTNM vs BWAY Comparison
Compare CTNM & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- BWAY
- Stock Information
- Founded
- CTNM 2009
- BWAY 2003
- Country
- CTNM United States
- BWAY Israel
- Employees
- CTNM N/A
- BWAY N/A
- Industry
- CTNM
- BWAY Medical/Dental Instruments
- Sector
- CTNM
- BWAY Health Care
- Exchange
- CTNM Nasdaq
- BWAY Nasdaq
- Market Cap
- CTNM 328.1M
- BWAY 280.7M
- IPO Year
- CTNM 2024
- BWAY 2019
- Fundamental
- Price
- CTNM $11.01
- BWAY $16.85
- Analyst Decision
- CTNM Strong Buy
- BWAY Strong Buy
- Analyst Count
- CTNM 5
- BWAY 2
- Target Price
- CTNM $22.20
- BWAY $18.00
- AVG Volume (30 Days)
- CTNM 92.7K
- BWAY 60.3K
- Earning Date
- CTNM 10-30-2025
- BWAY 11-11-2025
- Dividend Yield
- CTNM N/A
- BWAY N/A
- EPS Growth
- CTNM N/A
- BWAY 679.98
- EPS
- CTNM N/A
- BWAY 0.11
- Revenue
- CTNM N/A
- BWAY $46,084,000.00
- Revenue This Year
- CTNM N/A
- BWAY $335.63
- Revenue Next Year
- CTNM N/A
- BWAY $22.10
- P/E Ratio
- CTNM N/A
- BWAY $61.06
- Revenue Growth
- CTNM N/A
- BWAY 26.50
- 52 Week Low
- CTNM $3.35
- BWAY $7.84
- 52 Week High
- CTNM $20.24
- BWAY $17.49
- Technical
- Relative Strength Index (RSI)
- CTNM 48.88
- BWAY 62.59
- Support Level
- CTNM $10.77
- BWAY $16.44
- Resistance Level
- CTNM $11.34
- BWAY $17.20
- Average True Range (ATR)
- CTNM 0.68
- BWAY 0.72
- MACD
- CTNM -0.15
- BWAY 0.08
- Stochastic Oscillator
- CTNM 31.37
- BWAY 78.23
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.